Bolus vincristine and epirubicin with cyclophosphamide and dexamethasone (VECD) as induction and salvage treatment in multiple myeloma

Leukemia

Volumn 12, Issue 3, 1998, Pages 422-426

  Fossa A ^a,b   Muer, M ^a   Kasper, C ^a   Welt, A ^a   Seeber, S ^a   Nowrousian, M R ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

Chemotherapy; Cyclophosphamide; Epirubicin; Multiple myeloma; Non infusional; VAD

Indexed keywords

CYCLOPHOSPHAMIDE; DEXAMETHASONE; EPIRUBICIN; VINCRISTINE;

ADULT; AGED; ARTICLE; BOLUS INJECTION; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; LEUKOPENIA; MALE; MULTIPLE MYELOMA; NEUTROPENIA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SALVAGE THERAPY; SURVIVAL TIME;

EID: 0031932724     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2400945     Document Type: Article

References (26)

1. Camba L, Durie BGM. Multiple myeloma. New treatment options. Drugs 1992; 44: 170-181.
2. Bergsagel DE. Chemotherapy of myeloma. In : Malpas JS, Bergsagel DE, Kyle RA (eds). Myeloma. Biology and Management. Oxford University Press: New York, 1995, pp. 273-306.
3. Barlogie B, Smith L, Alexanian R. Effective treatment of advanced multiple myeloma refractory to alkylating agents. New Engl J Med 1984; 310: 1353-1356.
4. Drewinko B, Alexanian R, Boyer H, Barlogie B, Rubinow SI. The growth fraction of human myeloma cells. Blood 1981; 7: 333-338.
5. Alexanian R, Barlogie B, Tucker S. VAD-based regimens as primary treatment for multiple myeloma. Am J Hematol 1990; 33: 887-890.
6. Maitland JA, Millar BC, Bell JBG, Montes A, Treleaven J, Gore ME, McElwain TJ. Evidence that multiple myeloma may be regulated by homeostatic control mechanisms: correlation of changes in the number of clonogenic myeloma cells in vitro with clinical response. Br J Cancer 1990; 61: 429-433.
7. Brandes LJ, Israels LG. Treatment of advanced plasma cell myeloma with weekly cyclophosphamide and alternate day prednisone. Cancer Treat Rep 1982; 66: 1413-1415.
8. Lenhard RE, Oken MM, Barnes JM, Humphrey RL, Glick JH, Silverstein MN. High-dose cyclophosphamide. An effective treatment for advanced refractory multiple myeloma. Cancer 1984; 53: 1456-1460.
9. Durie BGM, Salmon SE. A clinical staging system for multiple myeloma: correlation of measured cell mass with presenting clinical features, response to treatment and survival. Cancer 1975; 36: 842-854.
10. Gore ME, Selby PJ, Viner C, Clark PI, Meldrum M, Millar B, Bell J, Maitland JA, Milan S, Judson IR, Zuiable A, Tillyer C, Slevin M, Malpas JS, McElwain TJ. Intensive treatment for multiple myeloma and criteria for complete remission. Lancet 1989; ii: 879-882.
11. Miller AB, Hoogstraten B, Staquet M. Reporting results of cancer treatment. Cancer 1981; 47: 207-214.
12. Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
13. Peto R, Peto J. Asymptomatically efficient invariant procedures. J Royal Stat Soc 1972; 135: 185-206.
14. Barlogie B, Jagannath S, Vesole DH, Naucke S, Cheson B, Mattox S, Bracy D, Salmon S, Jacobson J, Crowley J, Tricot G. Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood 1997; 89: 789-793.
15. Anderson H, Scarffe JH, Ranson M, Young R, Wieringa GS, Morgenstern GR, Fitzsimmons L, Ryder D. VAD chemotherapy as remission induction for multiple myeloma. Br J Cancer 1995; 71: 326-330.
16. Anderson H, Scarffe JH, Lambert M, Smith DB, Chan CC, Chadwick G, McMahon A, Chang J, Crowther D, Swindell R. VAD chemotherapy-toxicity and efficacy in patients with multiple myeloma and other lymphoid malignancies. Hematol Oncol 1987; 5: 213-222.
17. Raje N, Powles R, Kulkarni S, Milan S, Middleton G, Singhal S, Mehta J, Millar B, Viner C, Raymond J, Treleaven J, Cunningham D, Gore M. A comparison of vincristine and doxorubicin infusional chemotherapy with methylprednisolone (VAMP) with the addition of weekly cyclophosphamide (C-VAMP) as induction treatment followed by autografting in previously untreated myeloma. Br J Haematol 1997; 97: 153-160.
18. Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF, Cassus P, Maisonneuve H, Facon T, Ifrah N, Payen C, Bataille R. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. New Engl J Med 1996; 335: 91-97.
19. Oivanen TM. Prognostic value of serum M-protein doubling time at escape from plateau of multiple myeloma. Eur J Haematol 1996; 57: 247-253.
20. Lokhorst HM, Meuwissen OJAT, Bast EJEG, Dekker AW. VAD chemotherapy for refractory multiple myeloma. Br J Haematol 1989; 71: 25-30.
21. Stenzinger W, Blömker A, Hiddemann W, van de Loo J. Treatment of refractory multiple myeloma with the vincristine-adriamycin-dexamethasone (VAD) regimen. Blut 1990; 61: 55-59.
22. Scheithauer W, Cortelezzi A, Kutzmits R, Baldini L, Ludwig H. VAD protocol for treatment of advanced refractory multiple myeloma. Blut 1987; 55: 145-152.
23. Gertz MA, Kalish LA, Kyle RA, Hahn RG, Tormey DC, Oken MM. Phase III study comparing vincristine, doxorubicin (adriamycin), and dexamethasone (VAD) with VAD plus recombinant Interferon alfa-2 in refractory or relapsed multiple myeloma. Am J Clin Oncol 1995; 18: 475-480.
24. Barlogie B, Alexanian R. Therapy of primary resistant and relapsed multiple myeloma. Onkologie 1986; 9: 210-214.
25. Browman GP, Belch A, Skillings J, Wilson K, Bergsagel D, Johnston D, Pater JL. Modified adriamycin-vincristine-dexamethasone (m-VAD) in primary refractory and relapsed plasma cell myeloma: an NCI (Canada) pilot study. Br I Haematol 1992; 82: 555-559.
26. Palva IP, Ahrenberg P, Ara Harja K, Almqvist A, Elonen E, Hallman H, Hänninen A, Ilvonen M, Isomaa B, Jouppila J, Järvenpää E, Järventie G, Kilpi H, Koivunen E, Kätkä K, Kääriäinen M, Lahtinen A, Lehtinen M, Mäkelä H, Nyländen P, Nyman D, Oivanen T, Pakkala S, Pelliniemi T-T, Pulli T, Rajamäki A, Ruutu T, Savola J, Soininen K, Timonen T, Wasastjerna C, Vilpo J. Intensive chemotherapy with combinations containing anthracyclines for refractory and relapsing multiple myeloma, Eur J Haematol 1990; 44: 120-123.